Back to News & Events

Proposal Development Support – SBIR/STTR

The Center for Biotechnology is offering one-on-one SBIR/STTR proposal development counseling and iterative grant writing services to companies – application for next cohort is June 5th!

Companies that have completed our intensive 2-day workshop (or similar program) and/or have previously submitted an unsuccessful SBIR/STTR proposal in the past are eligible to apply. Services provided under this program are awarded through a competitive application process and include a weekly “best practices” proposal development webinar followed by iterative review of section drafts to guide stepwise development of the proposal from start to finish.

Companies selected for this follow-on counseling will be required to contribute $250 and will receive up to 10 hours of iterative proposal development services valued at $2000. These services will be subsidized by the Center for Biotechnology through the Downstate New York SBIR Assistance Program.
Interested companies should apply online no later than June 5, 2020. The application can be found here: https://forms.gle/5m9kAN8nUnzEyXyi9.

Contact Kate Hutchinson kate.hutchinson@stonybrook.edu with questions.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3880 [post_author] => 4 [post_date] => 2022-03-15 14:30:41 [post_date_gmt] => 2022-03-15 14:30:41 [post_content] =>

The Center for Biotechnology has announced a Call for Proposals for our 2022 Applied Research and Development (ARAD) Program. The ARAD program provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and NY State corporate partners in all areas of medical biotechnology.

These areas include research technologies, diagnostics, therapeutics and medical devices. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy.

2022 Proposal Submission:

The deadline for receipt of applications is April 15, 2022, 5pm. No exceptions will be made. Applications are accepted and considered on a competitive basis and are subject to the availability of funds. Approval from the Research Foundation Sponsored Programs is not required prior to submission, but will be required if the project is selected for funding. All applications require a letter-of-support from a senior executive of the company confirming their corporate residency in New York State and financial commitment to match-fund the project. Further details are found within the forms pages. A single PDF version of the proposal and letter of support should be submitted to Center for Biotechnology at center_for_biotechnology@stonybrook.edu.

ARAD Program Forms:
Call for Applications & Guidelines
Application Form
Budget Forms

[post_title] => Call for Proposals: Applied Research and Development Program [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => arad2022 [to_ping] => [pinged] => [post_modified] => 2022-12-13 17:05:39 [post_modified_gmt] => 2022-12-13 17:05:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3880 [menu_order] => 26 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 4470 [post_author] => 4 [post_date] => 2024-08-28 10:13:57 [post_date_gmt] => 2024-08-28 14:13:57 [post_content] =>

The Long Island High Technology Incubator (LIHTI) is inviting innovative and entrepreneurial individuals, with advanced training in STEMM disciplines, to join our team to support our Venture Champions Initiative. The VC Fellowship is powered by the LIHTI team, working collaboratively with a wide network of mentors and industry partners. In the long term, this fellowship aims to generate a pipeline of trained, entrepreneurially-minded fellows as well as a pool of commercially viable technologies for the Long Island Innovation ecosystem. Apply here to chart your commercialization career in hard tech.

[post_title] => LIHTI Venture Champion Fellowship [post_excerpt] => The Long Island High Technology Incubator is recruiting candidates for its Venture Champions Fellowship. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => lihti-fellowship24 [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:46:47 [post_modified_gmt] => 2024-11-19 15:46:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4470 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2064 [post_author] => 3 [post_date] => 2015-12-07 20:15:00 [post_date_gmt] => 2015-12-07 20:15:00 [post_content] => Accelerating Biomedical Discoveries for Commercialization STONY BROOK, N.Y. – December 7, 2015 - The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), announced today the recipients of the first technology development grants awarded by the Hub. Thirteen awards totaling $900,000 were granted to applicants from Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory. The LIBH technology development grants are a multi-tiered funding initiative aimed at collectively contributing to a pipeline of commercially promising biomedical technology in the region. The three funding initiatives include Feasibility, Proof of Concept and Commercialization awards. Feasibility awards are designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications of an existing technology.  Proof of Concept Awards provide targeted, milestone driven support for proof of concept research, development, testing, and analysis of existing intellectual property. The final tier, Commercialization Awards, provide targeted, milestone-driven support for a subset of projects with existing intellectual property where additional investment will clearly advance the technology to a major value inflection point for commercialization. The grants awarded this cycle will support technologies developed across multiple disciplines including pharmacology, biomedical engineering, chemistry, and microbiology. Among the award recipients were two post-doctoral researchers. Of the thirteen grants awarded, eight were Feasibility awards and five were Proof of Concept Awards. The recipients of this round of awards are: Feasibility awards
  • Targeting Pathogenic Viral Infections with First-In-Class Viral Budding Inhibitors - Dr. Carol Carter
  • Development of Small Molecule Inhibitors for PLD6 as Therapeutics for Triple Negative Breast Cancer - Dr. Michael Frohman
  • Novel miR-129 Based Therapeutics for Colon Cancer - Dr. Jingfang Ju
  • Fast Hybrid Approach For Determination of Structure of Therapeutic Protein Complexes - Dr. Dima Kosakov
  • Enhancement of Protein Yields Using Mechanical Signals: Augmenting Biotech Production to Reduce Drug Costs - Dr. Gabriel Pagnotti
  • Non-invasive Acoustic Radiation Force Therapy for OA Induced Pain and Cartilage Regeneration - Dr. Yixian Qin
  • LDL as Biomarker for Childhood Tuberculosis (TB) - Dr. Xinxin Yang
Proof of Concept awards
  • A New Standard of Care for Implant Bed Preparation Utilizing an Innovative Drill Bit Technology - Dr. Marcous Abboud
  • Orthovoltage X-Ray Minibeams: Brain Tumor Therapy with Tissue-sparing Incident Beams - Dr. Avraham Dilmanian
  • NEW‐HARP: A Highly Sensitive Avalanche Selenium Detector for Time‐of‐Flight (TOF) Positron Emission Tomography (PET) - Dr. Amirhossein Goldan
  • Azasteroids for Combination Anti-TB Therapy - Dr. Nicole Sampson
  • A Novel Glioblastoma Drug – Oncolytic Virus PV1-Mono-Cre - Dr. Eckard Wimmer
​“We are excited to see such a robust and diverse portfolio of early stage technologies supported through the LIBH and NIH-REACH consortium,” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “We are hopeful that this investment by the federal and state government, as well as SBU, CSHL and BNL, will foster and accelerate the translation of these technologies from the bench to the bed side, and help attract further investment from the industrial and financial sectors.” The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission. [post_title] => Long Island Bioscience Hub Announces Funded Projects [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-bioscience-hub-announces-funded-projects [to_ping] => [pinged] => [post_modified] => 2016-03-29 20:18:36 [post_modified_gmt] => 2016-03-29 20:18:36 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2064 [menu_order] => 195 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 261 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

Call for Proposals: Applied Research and Development Program

More Information

LIHTI Venture Champion Fellowship

More Information

Long Island Bioscience Hub Announces Funded Projects

More Information